Article

Recurrent Ovarian Cancer in BRCAness Phenotype: A Treatment Challenge

2022-02-22

Abstract excerpt

<h4>Background: </h4> Ovarian cancer is a leading cause of female death from gynecologic malignancies. The relapse rate is high after platinum-based therapy, with the effectiveness of subsequent treatment lines decreasing over time. Recent data suggest the benefit of maintenance therapy with niraparib in platinum-sensitive recurrent disease. Case presentation: Herein is reported a case series of five women with ad...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ba109ff0-1141-58c3-8b8c-0f25319e79a0
DOI: 10.21203/rs.3.rs-1374864/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Recurrent Ovarian Cancer in BRCAness Phenotype: A Treatment ChallengeDOI 10.21203/rs.3.rs-1374864/v1Read

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.Semantic proximity Read

Niraparib for the treatment of ovarian cancer.Semantic proximity Read

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingSemantic proximity Read

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experienceSemantic proximity Read

Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsSemantic proximity Read

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemSemantic proximity Read

Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.Semantic proximity Read

BRCAness: Finding the Achilles Heel in Ovarian CancerSemantic proximity Read

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challengesSemantic proximity Read

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian CancerSemantic proximity Read

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.Semantic proximity Read